SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Talk to Advisor
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

Remus Pharmaceuticals Ltd (REMUS)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: REMUS Trading | Small Cap | Remus Pharmaceutical Share Price

BSE Share Price
Not Listed

Remus Pharmaceuticals Ltd (REMUS)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: REMUS Trading | Small Cap | Remus Pharmaceutical Share Price

BSE Share Price
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹839 Cr.
Current Price
₹0
52-Week Low / High
₹0 / 0
TTM EPS
₹21
TTM Sales
₹94 Cr.
Book Value per Share
₹276.4
P/E Ratio
33.94
Lower than its 5-year historical median
Industry PE
36
Price to Book (P/B)
2.58
Lower than its 5-year historical median
Price to Sales (P/S)
8.92
Lower than its 5-year historical median
EV/EBITDA
22.88
Lower than its 5-year historical median
Dividend Yield
0.07%
Profitability Efficiency
Return on Equity (ROE)
10.06%
Outperforms industry median
Return on Capital Employed (ROCE)
13.53%
Outperforms industry median
Return on Assets (ROA)
8.58%
Operating Profit Margin
32.8%
Net Profit Margin
25.14%
Gross Profit Margin
36%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
23.8%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
23.71%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
19.74%
Asset Quality
Promoter Holding
70.95%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹314 Cr.
Equity
₹11.8 Cr.
Face Value
₹10
All Time Low / High
- / -

Remus Pharmaceuticals stock performance

Key Ratios
mw4me loader

Check Before You Invest

Check Before You Invest

Quality

Locked
Login to view analysis.

Valuation

Locked
Login to view analysis.

Price Trend

Locked
Login to view analysis.
Q.1 Is Remus Pharmaceuticals Ltd a good quality company?
Remus Pharmaceuticals Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

View More

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

View More
How does Remus Pharmaceuticals Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Remus Pharmaceuticals Ltd vs industry peers?
Remus Pharmaceuticals Ltd revenue CAGR is 46.03%, compared to the industry median CAGR of 0%, indicating faster growth and gaining its market share.
Q.1 Promoter shareholding and pledge status of Remus Pharmaceuticals Ltd?
Promoters hold 70.95% of the Remus Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Remus Pharmaceuticals Ltd over the last decade?
Over the last 1 year(s), the stock has delivered a CAGR of -60.06% based on the current price.
View More

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Remus Pharmaceuticals Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation ⓘ

Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % ⓘ47.8%48.8%93.1%68.8%24.9%13.5%-
Value Creation
Index ⓘ		2.42.55.73.90.80.0-

Growth Parameters ⓘ
Sales ⓘ11.918.424.74563.979.294
Sales YoY Gr.-54.5%34.1%82.3%42%23.8%-
Adj EPS ⓘ0.81.14.19.313.816.421
YoY Gr.-35.7%259.7%126.6%48.2%18.7%-
BVPS (₹) ⓘ2.53.88.222.1130.6205.6276.4
Adj Net
Profit ⓘ		0.70.93.38.116.219.325
Cash Flow from Ops. ⓘ1.32.855.36.315.6-
Debt/CF from Ops. ⓘ0.30.101.50.20.1-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘNA46%47.4%23.8%
Adj EPS ⓘNA81.1%58.6%18.7%
BVPSⓘNA141%192.5%57.5%
Share Price - - -32.3% -64.2%

Key Financial Parameters ⓘ

Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity % ⓘ		33.23668.162.718.89.78.7
Op. Profit
Mgn % ⓘ		3.34.116.723.432.832.8NAN
Net Profit
Mgn % ⓘ		5.6513.317.925.424.326.3
Debt to
Equity ⓘ		0.20.100.400-
Working Cap
Days ⓘ		0132155791402320
Cash Conv.
Cycle ⓘ		0-7-33-147300

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales121825456479
Operating Expenses ⓘ + 121821344353
Manufacturing Costs001122
Material Costs71112212835
Employee Cost 333579
Other Costs ⓘ 234676
Operating Profit ⓘ 014112126
Operating Profit Margin (%) 3.3%4.1%16.7%23.4%32.8%32.8%
Other Income ⓘ + 111233
Exceptional Items ⓘ 000000
Interest ⓘ 000000
Depreciation ⓘ 000012
Profit Before Tax ⓘ 115112227
Tax ⓘ 001367
Profit After Tax 11391720
PAT Margin (%) 6.8%5.6%13.9%18.9%26.0%25.1%
Adjusted EPS (₹)1.01.34.39.814.116.9
Dividend Payout Ratio (%)0%0%0%2.60%5.30%4.40%

Valuation of Remus Pharmaceutical - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 23719154242
Share Capital ⓘ 001116
Reserves ⓘ 23618152236
Debt +000812
Long Term Debt000712
Short Term Debt000100
Minority Interest000000
Trade Payables155485
Others Liabilities ⓘ 23442131
Total Liabilities ⓘ 5111635183280

Fixed Assets

Net Fixed Assets ⓘ +100357
Gross Block1113711
Accumulated Depreciation000124
CWIP ⓘ 000000
Investments ⓘ 00321127209
Inventories012022
Trade Receivables24351516
Cash Equivalents 1113114
Others Assets ⓘ 25732442
Total Assets ⓘ 5111635183280

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity ⓘ + 1355616
PBT ⓘ 115112227
Adjustment ⓘ 00-00-10
Changes in Working Capital ⓘ 022-3-9-4
Tax Paid ⓘ -0-0-1-3-6-8
Cash Flow From Investing Activity ⓘ + -1-3-5-15-47-12
Capex -1-0-0-3-3-4
Net Investments 0-0-3-18-43-7
Others ⓘ 0-3-15-1-2
Cash Flow From Financing Activity ⓘ + 0-0-01242-1
Net Proceeds from Shares ⓘ 0004470
Net Proceeds from Borrowing ⓘ 00-00-61
Interest Paid ⓘ -0-0-0-0-0-0
Dividend Paid ⓘ 0000-1-1
Others ⓘ 0-0082-0
Net Cash Flow ⓘ 1-00212

Financial Ratio

PARTICULARSMar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)40.1740.4971.3766.1419.2510.06
ROCE (%)47.7648.8493.1368.8224.9213.53
Asset Turnover Ratio2.262.261.841.790.590.34
PAT to CFO Conversion(x)131.670.560.350.8
Working Capital Days
Receivable Days49.8051.8048.1031.5055.5069.70
Inventory Days13.4015.7020.207.606.209.20
Payable Days67.90102.70146.3069.8077.2068.90

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Remus Pharmaceuticals Ltd FAQs

The current trading price of Remus Pharmaceutical on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Remus Pharmaceutical stood at ₹838.7 Cr

The latest P/E ratio of Remus Pharmaceutical as of 31-Dec-1969 is 33.94.

The latest P/B ratio of Remus Pharmaceutical as of 31-Dec-1969 is 2.58.

The 52-week high of Remus Pharmaceutical is ₹0.00 and the 52-week low is ₹0.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Remus Pharmaceutical is ₹93.99 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Remus Pharmaceuticals Ltd is a good quality company.

The key valuation ratios of Remus Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Remus Pharmaceuticals Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

About Remus Pharmaceuticals Ltd

The company was originally incorporated as ‘Remus Pharmaceuticals Private Limited’ as a private limited company, under the provisions of the Companies Act, 2013 vide Certificate of Incorporation dated September 21, 2015, issued by the Assistant Registrar of Companies, Gujarat. Later on, pursuant to a special resolution passed by its shareholders in the Extra-Ordinary General Meeting held on January 02, 2023, the company was converted from a private limited company to public limited company and consequently, the name of the company was changed to ‘Remus Pharmaceuticals Limited’, and a fresh certificate of incorporation dated January 06, 2023 was issued to the company by the Registrar of Companies, Ahmedabad. 

The company is engaged in marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for preparation of reports on the dossiers of the products to be registered by them in various countries. Having cultivated strong and dependable customer relationships ranging from Generic distributors, regional distributors and Multinational distributors to Hospitals and Clinics through a responsive distribution network, its clients are spread in various countries. It looks forward to form long lasting relationships that enhance the lives of its patients.

The company is majorly engrossed in the pharmaceutical business involving marketing, trading and distribution of wide range of pharmaceutical finished formulations and products. Depending upon business requirements, it gets finished pharmaceutical formulations manufactured on loan license or contract manufacturing. Such manufacturing is on principle to principle basis. It has its presence through registered and/or under registration products in countries namely Bhutan, Bolivia, Chile, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Honduras, Jamaica, Kuwait, Madagascar, Malaysia, Hong Kong, Myanmar, Panama, Trinidad and Tobago, Uzbekistan, Venezuela, Vietnam etc. It deals in drug forms like Capsules, Cream, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nail Lacquer, Nasal Solution, Nasal Spray, Nebuliser, Ointment, Ophthalmic, Oral Gel, Oral Solution, Oral Suspension, Sachet, Suspension, Tablet.

Business area of the company

The company is engaged in marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient).

Products of the company

  • Cardiovascular
  • Anti-DIABETIC
  • Central nervous system
  • Analgesic / Anti-Inflammatory
  • Anti-Allergy
  • Anti-Infective / Anti biotics 
  • Hormonal
  • Urology
  • Immuno suppressant
  • Erectile dysfunction
  • Effervescent
  • Other formulations

History and milestones

  • 2015: The company was incorporated as a private limited company under the name ‘Remus Pharmaceuticals Private Limited’.
  • 2023: Conversion of the company from Private Limited to Public Limited Company.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×